Apolipoprotein Inhibitor

2′-O-Methyluridine (Standard) is the analytical standard of 2′-O-Methyluridine (HY-W001824). This product is intended for research and analytical applications. 2’-O-Methyluridine is a modified nucleoside that can be found in T. thermophile tRNA. 2’-O-Methyluridine level in serum is decreased in patients with breast cancer.

Mipomersen sodium scrambled negative control is the sequence scrambled negative control of Mipomersen sodium.

APOC3 Human Pre-designed siRNA Set A contains three designed siRNAs for APOC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lp(a)-IN-8 is a Lp(a) assembly inhibitor with an IC₅₀ of 0.749 nM. Lp(a)-IN-8 can be used in studies related to cardiovascular diseases and elevated plasma Lp(a) levels.

Alcedaplin (MZE829) is an Apolipoprotein L1 (ApoL1) function inhibitor.

APOL1-IN-3 (Compound 1) is an APOL1 inhibitor. APOL1-IN-3 can be used in the research of kidney diseases.

FAM labled Zerlasiran sodium is a FAM labled Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.

Obicetrapib (TA-8995; DEZ-001) potassium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potassium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib potassium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).

APOL1-IN-2 (Compound 467) is the inhibitor for Apolipoprotein 1 (APOL1). APOL1-IN-2 reduces the APOL1 G2/G1 induced cell death in HEK293 with EC₅₀ of 4.74 nM and 14.3 nM. APOL1-IN-2 reduces the APOL1 G2/G1/G0 induced death of trypanosomes with EC₅₀ of 2.24, 6.03 and 3.72 nM, respectively.

Tiadenol is an orally effective lipid-lowering compound and peroxisome proliferator. Tiadenol promotes peroxisome-associated fatty acid metabolism, and its induction of the activities of enzymes such as palmitoyl-CoA hydrolase, carnitine acetyl-transferase and catalase is mainly associated with de novo protein synthesis. The triglyceride-lowering effect of Tiadenol is not accompanied by increased activities of lipoprotein lipase (LPL) and hepatic lipase (HL), and it reduces VLDL Apo E. Tiadenol can be used in studies related to lipid metabolism, peroxisome proliferation and hyperlipoproteinemia.

5(Z),11(Z),14(Z)-Eicosatrienoic acid (Sciadonic acid), a polyunsaturated fatty acid sourced from maritime pine seed oil, gymnospermae leaves and seeds, and freshwater gastropods, has been shown to reduce high-density lipoprotein and ApoA1 levels in transgenic mice expressing human ApoA1 when included in their diet. In vitro studies indicate that it diminishes cholesterol efflux, and when applied topically in its methyl ester form, it alleviates inflammatory processes, likely by displacing arachidonic acid from phospholipid pools and lowering concentrations of downstream inflammatory mediators such as prostaglandin E2 and leukotrienes.

STT-5058 (ARGX-116; NN5058) is a human monoclonal antibody targeting ApoC3 and belongs to the class of ApoC3 inhibitors. STT-5058 exhibits pH-dependent circulation properties and binds to a unique epitope on ApoC3. STT-5058 reduces triglyceride levels and accelerates the clearance of atherogenic remnant lipoproteins containing ApoC3. STT-5058 can be used in research related to hypertriglyceridemia, dyslipidemia and cardiovascular diseases.

Opemalirsen is an antisense oligonucleotide targeted to apolipoprotein L1 (APOL1). It is used for the study of Kidney disorders.

Lepodisiran (LY3819469) sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease.

Opemalirsen sodium scrambled negative control is the sequence scrambled negative control of Opemalirsen sodium.

MEDI-5884 (REG-101) is a humanized IgG4Pκ neutralizing monoclonal antibody targeting endothelial lipase (EL), with an IC₅₀ of 1.3 nM and 1.7 nM against human and cynomolgus monkey EL, respectively; its K_d values for human and cynomolgus monkey EL are 4.1 nM and 1.6 nM, respectively. MEDI-5884 increases plasma levels of HDL-C, apolipoprotein A1 (ApoA1) and phospholipids, while causing a slight increase in LDL-C and apolipoprotein B (ApoB) levels. MEDI-5884 can be used in research related to cardiovascular diseases, coronary heart disease, coronary atherosclerosis and stable coronary artery disease.

Lp(a)-IN-5 (Compound A) hydrochloride is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 hydrochloride inhibits the assembly of Apo(a) and ApoB proteins with an IC₅₀ value of 0.41 nM. Lp(a)-IN-5 hydrochloride is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases.

Plozasiran sodium scrambled negative control is the sequence scrambled negative control of Plozasiran sodium.

Obicetrapib (TA-8995; DEZ-001) sodium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib sodium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib sodium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).

Lp(a)-IN-7 (example 1) is a lipoprotein (a) (Lp(a)) formation inhibitor with an IC₅₀ of 2.51 nM in conditioned media containing apolipoprotein B (apoB) and apolipoprotein(a). Lp(a)-IN-7 can be used for the study of cardiovascular disease.